TCI Wealth Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

TCI Wealth Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-278	Closed	-$19K	–	2717
2022 Q3	$19K	Hold	278	–	–	﹤0.01%	692
2022 Q2	$9K	Buy	278 +74	+36%	+$2.17K	﹤0.01%	1121
2022 Q1	$7K	Buy	+204	New	+$6.1K	﹤0.01%	1379
2021 Q4	–	Sell	-120	Closed	-$3K	–	2613
2021 Q3	$3K	Buy	+120	New	+$3.53K	﹤0.01%	2075
2020 Q4	–	Sell	-100	Closed	-$6K	–	1715
2020 Q3	$6K	Hold	100	–	–	﹤0.01%	741
2020 Q2	$6K	Hold	100	–	–	﹤0.01%	712
2020 Q1	$5K	Hold	100	–	–	﹤0.01%	742
2019 Q4	$8K	Buy	+100	New	+$5.93K	﹤0.01%	765

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

TCI Wealth Advisors's GBT Position: Q4 2022 in Review

TCI Wealth Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 278 shares — an estimated $19K sold.

TCI Wealth Advisors first reported a position in GBT in Q4 2019 and held it in 8 quarters. The position peaked at $19K in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

TCI Wealth Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
TCI Wealth Advisors sold 278 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $19K.
TCI Wealth Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 8 quarters.
TCI Wealth Advisors's Global Blood Therapeutics, Inc. position peaked at $19K in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on TCI Wealth Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.